October 25, 2024 – Page 8

Pacific Financial Corp Earns $2.6 Million, or $0.25 per Diluted Share for Third Quarter 2024; Tangible Book Value Per Share Up 6.6% During Quarter; Board of Directors Declares Quarterly Cash Dividend of $0.14 per Share

Written by Customer Service on October 25, 2024. Posted in Earnings Releases And Operating Results.

ABERDEEN, Wash., Oct. 25, 2024 (GLOBE NEWSWIRE) — Pacific Financial Corporation (OTCQX: PFLC), (“Pacific Financial”) or the (“Company”), the holding company for Bank of the Pacific (the “Bank”), reported net income of $2.6 million, or $0.25 per diluted share for the third quarter of 2024, compared to $2.1 million, or $0.21 per diluted share for the second quarter of 2024, and $3.6 million, or $0.35 per diluted share for the third quarter of 2023. All results are unaudited. Pacific Financials’ third quarter 2024 operating results reflected the following changes from the second quarter of 2024: (1) higher net interest income as the rise in loan and investment yields outpaced the rise in deposit and borrowing costs; (2) a negative provision for credit losses due to lower provision for unfunded loans; (3) lower non-interest income...

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

Written by Customer Service on October 25, 2024. Posted in Public Companies.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference, November 19-20, 2024. Members of the management team will host one-on-one meetings on both days. Alvotech will be presenting at the conference on Tuesday, November 19, 2024 at 9:00-9:25 am GMT. An audio webcast of the conference presentation will also be available to investors and the general public and can be accessed in the Investors Section of Alvotech’s website under News and Events – Events and Presentations. After the event, a recording will also be available for 90 days. About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines...

Abercrombie & Fitch Co. to Report Third Quarter 2024 Results on November 26, 2024

Written by Customer Service on October 25, 2024. Posted in Public Companies.

NEW ALBANY, Ohio, Oct. 25, 2024 (GLOBE NEWSWIRE) — Abercrombie & Fitch Co. (NYSE: ANF) will host its quarterly earnings conference call for all interested parties on Tuesday, November 26, 2024, at 8:30 a.m. ET. A press release detailing the company’s third quarter results is expected to be issued shortly after 7:30 a.m. ET. In addition, a presentation of the third quarter results will be available on the company’s website at approximately 7:30 a.m. ET. Conference Call: To access the conference call by phone, participants will need to register to obtain a dial-in phone number and an access code. Register for the call using this link. Webcast: To listen to a live webcast of the call, please visit corporate.abercrombie.com/investors/news-and-events/events/ and click the link to the webcast. Replay: A replay...

Oxford Lane Capital Corp. Schedules Second Fiscal Quarter Earnings Release and Conference Call for November 1, 2024

Written by Customer Service on October 25, 2024. Posted in Public Companies.

GREENWICH, Conn., Oct. 25, 2024 (GLOBE NEWSWIRE) — Oxford Lane Capital Corp. (Nasdaq: OXLC) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) (NasdaqGS: OXLCI) announced today that it will hold a conference call to discuss its second fiscal quarter earnings on Friday, November 1, 2024 at 9:00 AM ET. The toll-free dial-in number is 1-833-470-1428, access code number 436588. There will be a recorded replay of the call available for 30 days after the call. If you are interested in hearing the recording, please dial 1-866-813-9403. The replay pass-code number is 813197. About Oxford Lane Capital Corp. Oxford Lane Capital Corp. is a publicly-traded registered closed-end management investment company principally investing in debt and equity tranches of collateralized loan obligation (“CLO”) vehicles....

Financial Calendar – Icelandic Salmon

Written by Customer Service on October 25, 2024. Posted in Public Companies.

Bíldudalur, 25th of October 2024. FINANCIAL YEAR 2024 18.11.2024 – Quarterly Report – Q3 18.02.2025 – Quarterly Report – Q4 25.4.2025 – Annual Report 2024 FINANCIAL YEAR 2025 20.05.2025 – Quarterly Report – Q1 18.06.2025 – Annual General Meeting 21.08.2025 – Half-yearly Report 06.11.2025 – Quarterly Report – Q3 Changed date for Q3 2024 reporting Please note that the dates are subject to change. Changes will be communicated through Stock Exchange announcements and the company’s homepage, www.arnarlax.is. The results will be published through the company’s homepage, and other newswires at about 06:30 am CET.

Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Written by Customer Service on October 25, 2024. Posted in Public Companies.

CHATHAM, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Wednesday, October 30, 2024, at 9:30 a.m. ET, and host investor meetings. The conference is being held at the Mandarin Oriental, New York in New York City. Investors interested in arranging a meeting with the Company’s management during the conference should contact the ThinkEquity conference coordinator. A webcast of the presentation will be available under the IR Events tab of the Tonix website at www.tonixpharma.com. Tonix Pharmaceuticals Holding Corp.* Tonix is a...

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

Written by Customer Service on October 25, 2024. Posted in Public Companies.

REYKJAVIK, Iceland, Oct. 25, 2024 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference, November 19-20, 2024. Members of the management team will host one-on-one meetings on both days. Alvotech will be presenting at the conference on Tuesday, November 19, 2024 at 9:00-9:25 am GMT. An audio webcast of the conference presentation will also be available to investors and the general public and can be accessed in the Investors Section of Alvotech’s website under News and Events – Events and Presentations. After the event, a recording will also be available for 90 days. About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused...

Hurco Poised to Pioneer the Future of Manufacturing

Written by Customer Service on October 25, 2024. Posted in Public Companies.

INDIANAPOLIS, Oct. 25, 2024 (GLOBE NEWSWIRE) — Hurco Companies, Inc. (Nasdaq: HURC), announced today its vision to drive the future of Autonomous Machining Centers by harnessing the power of AI, mechatronics, motion, and simulation technologies. Greg Volovic, President and CEO of Hurco, said, “Building on the successful consolidation of Hurco, Milltronics, and Takumi PC hardware, we plan to transform manufacturing by reshaping industry standards and revolutionizing our market presence with cutting-edge technologies that advance automation and connectivity to address the labor challenges that continue to inhibit growth for our customers.” “Our research and development of AI-driven capabilities, such as feature detection, operation sequencing, and process control, will be critical to realizing our bold vision where Autonomous Machining...

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Written by Customer Service on October 25, 2024. Posted in Public Companies.

Name Change Reflects Extensive Scientific and Corporate Brand Equity Previously Established under Grace Therapeutics Grace Therapeutics will begin trading on Nasdaq under the trading symbol “GRCE” effective October 28, 2024 Virtual Key Opinion Leader Event to be held on November 20th PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTx-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that it is changing its name to Grace Therapeutics, Inc. (Grace Therapeutics). Grace Therapeutics was the name of the company developing GTx-104 prior to its merger with Acasti in 2021. Grace Therapeutics will begin...

Aspira Women’s Health Issues Letter to Shareholders and Announces Virtual Research & Development Day on October 29, 2024

Written by Customer Service on October 25, 2024. Posted in Public Companies.

Event to feature presentations from Dr. Kevin Elias, Dr. Richard Gersh, Dr. Sandra Milligan, and Dr. Todd Pappas on the Company’s development pipeline AUSTIN, Texas, Oct. 25, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, has issued a letter to Company shareholders and announced it will host a virtual Research & Development Day on Tuesday, October 29, 2024, at 3:00 pm ET. The R&D Day will highlight the company’s plans for its miRNA development pipeline, including the recently announced award from the Advanced Research Project Agency for Health (ARPA-H)’s Sprint for Women’s Health initiative for ENDOinform™. Details for the event are as follows: Date: October 29, 2024 Time: 3:00...

Day: October 25, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice